MedTrace Logo

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

NCT07129187 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-26

No results posted yet for this study

Summary

This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant regimen. Patients who were determined by the researchers to have poor therapeutic effect will switch to SHR-A1811.

Conditions

  • Early Breast Cancer
  • HER2 + Breast Cancer
  • Stage II Breast Cancer
  • Stage III Breast Cancer

Interventions

DRUG

SHR-A1811

Drug: SHR-A1811 4.8mg/kg

Sponsors & Collaborators

  • Chuan Wang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2026-10-31
Completion
2030-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07129187 on ClinicalTrials.gov